IPM Take
The most important thing about a future TB vaccine may be what happens before it arrives. Too often, countries with the greatest burden are asked to wait for a product, then wait again for funding, guidance, supply and delivery systems. Kenya, Malawi and Zambia are trying to reverse that sequence. Their message is straightforward: if a new TB vaccine is licensed, the access pathway cannot still be sitting in a meeting room.
Executive Summary
WHO reported that officials from Kenya, Malawi and Zambia had met in Nairobi with TB survivors, civil-society representatives, regulators, donors and technical partners to prepare for potential introduction of new TB vaccines for adults and adolescents. Several vaccine candidates are still in clinical development, but WHO says a new product could be licensed as early as 2029, depending on trial results. The countries are now developing early road maps on target populations, delivery strategies, regulatory evidence, financing and community engagement. (World Health Organization)
Why it matters
- Public authorities: Need to build adoption, financing and delivery plans before a future product reaches the market.
- Policymakers: Need to ensure that high-burden countries are not last in line once efficacy data arrive.
- Patients / advocates: Must be involved early, because trust and community acceptance cannot be added at the end.
This is what access planning should look like: early, imperfect and serious.
The workshop was not a launch of a vaccine. It was an attempt to stop another access gap before it is created. WHO estimates that, over 25 years, a TB vaccine with 50% efficacy could avert up to 76 million new cases and 8.5 million deaths, while reducing household costs faced by people affected by TB. But those gains are theoretical unless national systems know who should be vaccinated, where doses will be delivered and how services will reach adults and adolescents who rarely move through routine childhood immunisation channels. (World Health Organization)
The political significance lies in who was in the room. Kenya, Malawi and Zambia brought together TB and immunisation teams, regulatory agencies, civil society, donors and people with lived experience of TB. WHO says the discussion covered country-specific road maps, priority populations, evidence needs, financing and links to national TB and immunisation strategies.
That matters because adult TB vaccination will not travel through a single, ready-made route. It may need to reach people through clinics, workplaces, schools, community services, HIV programmes or other local touchpoints. Each route brings its own questions of eligibility, consent, trust, supply and follow-up.
For IPM, this is a rare example of the last mile being built before the science is finished. The countries are not pretending approval is guaranteed. They are recognising that waiting until approval would be a choice, and a costly one.
